Novel inhibitors of human immunodeficiency virus type 2 infectivity-Reference-Cited by-同舟云学术

Novel inhibitors of human immunodeficiency virus type 2 infectivity

Published:2014-12-01 Issue:12 Volume:95 Page:2778-2783
ISSN:0022-1317
Container-title:Journal of General Virology
language:en
Short-container-title:

Author:

Beach Lauren B.¹²,Rawson Jonathan M.¹²,Kim Baek³,Patterson Steven E.⁴²,Mansky Louis M.⁴¹²⁵⁶

Affiliation:

1. Molecular, Cellular, Developmental Biology & Genetics Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA

2. Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA

3. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

4. Center for Drug Design, University of Minnesota, Minneapolis, MN 55455, USA

5. Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA

6. Department of Microbiology, University of Minnesota, Minneapolis, MN 55455, USA

Abstract

Human immunodeficiency virus type 2 (HIV-2) infects about two million people worldwide. HIV-2 has fewer treatment options than HIV-1, yet may evolve drug resistance more quickly. We have analysed several novel drugs for anti-HIV-2 activity. It was observed that 5-azacytidine, clofarabine, gemcitabine and resveratrol have potent anti-HIV-2 activity. The EC50 values for 5-azacytidine, clofarabine and resveratrol were found to be significantly lower with HIV-2 than with HIV-1. A time-of-addition assay was used to analyse the ability of these drugs to interfere with HIV-2 replication. Reverse transcription was the likely target for antiretroviral activity. Taken together, several novel drugs have been discovered to have activity against HIV-2. Based upon their known activities, these drugs may elicit enhanced HIV-2 mutagenesis and therefore be useful for inducing HIV-2 lethal mutagenesis. In addition, the data are consistent with HIV-2 reverse transcriptase being more sensitive than HIV-1 reverse transcriptase to dNTP pool alterations.

Publisher

Microbiology Society

Subject

Virology

Reference43 articles.

1. HIV/Simian Immunodeficiency Virus (SIV) Accessory Virulence Factor Vpx Loads the Host Cell Restriction Factor SAMHD1 onto the E3 Ubiquitin Ligase Complex CRL4DCAF1

2. Anti-HIV Host Factor SAMHD1 Regulates Viral Sensitivity to Nucleoside Reverse Transcriptase Inhibitors via Modulation of Cellular Deoxyribonucleoside Triphosphate (dNTP) Levels

3. HIV-2 Antiviral Potency and Selection of Drug Resistance Mutations by the Integrase Strand Transfer Inhibitor Elvitegravir and NRTIs Emtricitabine and Tenofovir In Vitro

4. SAMHD1 restricts HIV-1 infection in resting CD4+ T cells

5. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1;Balzarini;Curr Top Med Chem,2004

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the Therapeutic and Pharmacological Properties of Resveratrol as a Nutraceutical Antioxidant Polyphenol in Health Promotion and Disease Prevention;Current Reviews in Clinical and Experimental Pharmacology;2024-11

2. Human Immunodeficiency Virus Type 2 Capsid Protein Mutagenesis Reveals Amino Acid Residues Important for Virus Particle Assembly;Journal of Molecular Biology;2022-10

3. Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19;Frontiers in Pharmacology;2022-06-02

4. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity;Viruses;2022-04-18

5. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 – A formulator’s perspective;Biomedicine & Pharmacotherapy;2022-04